SUNNYVALE, Calif., –Cepheid (Nasdaq: CPHD) and the Knight Cancer Institute at Oregon Health & Science University (OHSU) today announced a collaboration to develop a menu of advanced molecular diagnostics to be performed on the GeneXpert system. The collaboration will focus on the development of clinical oncology tests for the GeneXpert system and will establish a […]

Menlo Park, CA –– Personalis, Inc. today announced availability of its Genome Services for Research, focusing on accuracy in sequencing, analysis, and interpretation of human genomes. Personalis believes that accuracy is crucial in medicine, both in research and ultimately in clinical use. We support researchers engaging in case-control, family-based, or proband-only genome studies of disease, […]

Redwood City, CA – – Ingenuity® Systems, a leading provider of biomedical information and analysis solutions, today announced that it has passed the Health Insurance Portability and Accountability Act (HIPAA) audit, confirming that Ingenuity’s data center and Ingenuity Variant Analysis are in compliance with relevant Federal Regulations. HIPAA Certification mandates strong security controls for managing […]

SUNNYVALE, Calif., — Cepheid (Nasdaq: CPHD) today announced that its Board of Directors has elected John Bishop as Chairman of the Board of Directors and named Cristina Kepner as Lead Independent Director, effective February 12, 2013. Mr. Bishop, currently Cepheid’s Chief Executive Officer, succeeds Thomas Gutshall, who will continue to serve on Cepheid’s board as […]

Saugus, MA, — IonSense, Inc. will be presenting new research on Direct Analysis in Real Time (DART) mass spectrometry analysis of drugs of abuse. The method involves a simplified protocol for the extraction of samples using a solid-phase coated metal probe, which is then analyzed directly using the DART source coupled to the MS instrument. […]

Hilden, Germany, and Germantown, Maryland, — QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced it has entered into a master collaboration agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas. The agreement builds on QIAGEN […]

Carlsbad, CA. – Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today that its GenASIs Scan & Analysis automated microscopy platform has received FDA clearance as an aid in ALK gene analysis for lung cancer therapy selection. The introduction of automation in ALK therapy selection represents a new era in personalized medicine for patients with NSCLC (Non-Small-Cell-Lung-Cancer). […]

GLOSTRUP, Denmark, – Dako, an Agilent Technologies company, announced today it has entered into a collaboration agreement with Pfizer in the field of companion diagnostics. The agreement constitutes a legal framework for various collaboration projects between the two companies, covering research, development and commercialization as well as advisory services. “We are extremely excited to partner […]

NISKAYUNA, NY, – Vanderbilt University has partnered with GE Global Research, the technology development arm for the General Electric Company (NYSE: GE), to better define – at the cellular level – how colon tumors form and develop. The research, supported by a five-year, $3.75 million grant from the Office of the Director of the National […]

Agilent Technologies Inc. (NYSE: A) and Sera Prognostics Inc., a women’s health company, today announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications. Sera Prognostics is currently developing a novel test for the early prediction of preterm birth risk using advanced proteomic science. Agilent is a leading provider of […]